BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $182,828.80 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 6,160 shares of the business’s stock in a transaction dated Friday, May 14th. The shares were sold at an average price of $29.68, for a total transaction of $182,828.80. Following the completion of the transaction, the chief marketing officer now owns 85,726 shares in the company, valued at $2,544,347.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Todd Berard also recently made the following trade(s):

  • On Friday, April 16th, Todd Berard sold 6,160 shares of BioLife Solutions stock. The shares were sold at an average price of $33.38, for a total transaction of $205,620.80.
  • On Thursday, April 1st, Todd Berard sold 2,825 shares of BioLife Solutions stock. The shares were sold at an average price of $36.53, for a total transaction of $103,197.25.
  • On Friday, March 26th, Todd Berard sold 2,120 shares of BioLife Solutions stock. The shares were sold at an average price of $35.01, for a total transaction of $74,221.20.
  • On Tuesday, March 16th, Todd Berard sold 6,160 shares of BioLife Solutions stock. The stock was sold at an average price of $36.72, for a total transaction of $226,195.20.
  • On Thursday, February 18th, Todd Berard sold 1,882 shares of BioLife Solutions stock. The stock was sold at an average price of $40.67, for a total transaction of $76,540.94.
  • On Tuesday, February 16th, Todd Berard sold 12,324 shares of BioLife Solutions stock. The stock was sold at an average price of $44.48, for a total transaction of $548,171.52.

NASDAQ:BLFS traded up $0.82 during trading hours on Monday, hitting $30.56. The stock had a trading volume of 256,257 shares, compared to its average volume of 300,547. BioLife Solutions, Inc. has a one year low of $14.43 and a one year high of $47.97. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -41.86, a P/E/G ratio of 50.41 and a beta of 1.55. The business’s 50 day moving average is $33.72 and its 200-day moving average is $37.30.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Wednesday, May 12th. The medical equipment provider reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.02). BioLife Solutions had a net margin of 12.67% and a return on equity of 0.53%. As a group, sell-side analysts expect that BioLife Solutions, Inc. will post 0.01 EPS for the current fiscal year.

A number of equities analysts have weighed in on the stock. Maxim Group boosted their target price on shares of BioLife Solutions from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, March 23rd. Benchmark downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Friday. TheStreet downgraded shares of BioLife Solutions from a “c-” rating to a “d+” rating in a research note on Friday, May 7th. B. Riley boosted their price target on shares of BioLife Solutions from $35.50 to $61.00 in a research note on Wednesday, March 24th. Finally, KeyCorp boosted their price target on shares of BioLife Solutions from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 29th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $45.10.

A number of large investors have recently modified their holdings of BLFS. Geneva Capital Management LLC bought a new stake in BioLife Solutions in the first quarter valued at approximately $37,191,000. Tower House Partners LLP bought a new stake in BioLife Solutions in the fourth quarter valued at approximately $18,872,000. Jennison Associates LLC acquired a new position in shares of BioLife Solutions in the fourth quarter valued at approximately $17,934,000. Palisade Capital Management LLC NJ acquired a new position in shares of BioLife Solutions in the first quarter valued at approximately $13,648,000. Finally, RMB Capital Management LLC acquired a new position in shares of BioLife Solutions in the first quarter valued at approximately $6,980,000. 67.66% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Story: Diversification Important in Investing

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.